by Progenra | May 26, 2020 | Blog
May 2020. Progenra has received new funding for its Michael J. Fox Foundation Therapeutic Pipeline Award, Discovery and Development of Novel Parkin Activators. Progenra’s novel Parkin activator molecules are undergoing preclinical development, and this funding will...
by Progenra | May 26, 2020 | Blog
February 2020. Ubiquitin-specific proteases (USPs), the major class of deubiquitinating enzymes, or DUBs, remove conjugated ubiquitin from proteins in cells and in so doing help to regulate the content, location, or activity of the target protein. Approximately 80...
by Progenra | May 15, 2019 | Blog
Abstract- The ubiquitin-specific protease 7 (USP7) has emerged as an attractive antitumor target due to its critical roles in several cancer signaling pathways as well as its essential role in maintaining Foxp3+ T-regulatory cell (Treg) functions. Pharmacological...
by Progenra | May 15, 2019 | Blog
Abstract- There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular...
by Progenra | May 14, 2019 | Blog
Abstract – Protein ubiquitination is an important means of post-translational modification which plays an essential role in the regulation of various aspects of leukocyte development and function. The specificity of ubiquitin tagging to a protein substrate is...
by Progenra | May 14, 2019 | Blog
Abstract- Mammalian cells remove misfolded proteins using various proteolytic systems, including the ubiquitin (Ub)-proteasome system (UPS), chaperone mediated autophagy (CMA) and macroautophagy. The majority of misfolded proteins are degraded by the UPS, in which...
